Analysis: Julie Johnson's sell of ABT (Abbott Laboratories)
Assessment: Low signal
A typical, small-scale periodic trim of an existing holding by a member with no relevant committee assignments, contradicted by positive insider buying.
- Member: Julie Johnson
- Party / state: Democratic-TX
- Chamber: House
- Transaction: Sell
- Amount: $1,001 - $15,000
- Ticker: ABT
- Company: Abbott Laboratories
- Trade date: 2026-05-12
- Disclosure date: 2026-06-12
- Disclosure lag: 31 days
Executive summary
On 2026-05-12, Rep. Julie Johnson (D-TX) reported a sale of Abbott Laboratories (ABT) valued at $1,001-$15,000, disclosed on 2026-06-12 (31-day lag). Within the provided dataset, ABT appears only as repeated small-dollar sales by the member (4 sales; no recorded buys). Available SEC context in the 90-day pre-trade window includes multiple 8-K filings (notably an acquisition completion and earnings release) and Form 4 activity showing net insider buying in late April 2026.
In the user-provided trading history (2025-01-15 to 2026-05-12; 501 trades across 227 tickers), the member’s ABT activity consists exclusively of sales in the same smallest reported range ($1,001-$15,000) across four dates (2025-08-14, 2025-11-13, 2025-12-18, 2026-05-12). The analyzed ABT sale occurred on the same day as a second sale (ACN) in the same size range, indicating at least a two-name same-day sell batch in the dataset. SEC EDGAR context provided in the prompt shows Abbott filed several 8-Ks in the months preceding the trade, including completion of the acquisition of Exact Sciences (8-K filed 2026-03-23) and a Q1 2026 results announcement (8-K filed 2026-04-16). Form 4 activity listed in the prompt includes two open-market/private purchases (CFO on 2026-04-23 and a director on 2026-04-27) and no sales within the provided window. Due to the inability to access Congress.gov, Federal Register, Regulations.gov, USAspending, and general news in this environment, this report cannot add independently verified legislative/regulatory/contracting context beyond the user-provided SEC enrichment.
Timeline
- 2026-02-20 — Abbott 8-K filed (Items 5.03, 9.01) – bylaw amendment re: Board size (per 8-K header/preview).
- 2026-02-26 — Abbott 8-K filed (Items 1.01, 9.01) – pricing agreement related to senior notes offering (per 8-K preview).
- 2026-03-09 — Abbott 8-K filed (Items 1.01, 2.03, 9.01) – completion of public offering/issuance of senior notes (per 8-K preview).
- 2026-03-23 — Abbott 8-K filed (Items 8.01, 9.01) – completion of acquisition of Exact Sciences Corporation (per 8-K preview and Exhibit 99.1 headline).
- 2026-04-16 — Abbott 8-K filed (Items 2.02, 9.01) – announced Q1 2026 results (per 8-K preview).
- 2026-04-17 — Abbott 8-K filed (Items 8.01, 9.01) – notice of proposed settlement in consolidated derivative litigation (Exhibit 99.1 includes settlement hearing date June 4, 2026).
- 2026-04-23 — Form 4: CFO Philip P. Boudreau reported open market/private purchase (2,200 shares at $91.50) (per user-provided Form 4 activity list).
- 2026-04-27 — Form 4: Director Daniel J. Starks reported open market/private purchase (10,000 shares at ~$92.6537) (per user-provided Form 4 activity list).
- 2026-04-27 — Abbott 8-K filed (Items 5.02, 5.03, 5.07, 9.01) – board/charter/governance items (per 8-K header/preview).
- 2026-05-12 — Rep. Julie Johnson sold ABT, $1,001-$15,000 (self). Same day also sold ACN, $1,001-$15,000 (self).
- 2026-06-04 — Settlement hearing scheduled in In re Abbott Laboratories Infant Formula Shareholder Derivative Litigation (date/time/location stated in Exhibit 99.1 to the 2026-04-17 8-K).
- 2026-06-12 — Trade disclosed (PTR filing date) for ABT sale executed 2026-05-12.
Independent analysis of public financial disclosures. Not financial or investment advice.